Showing 4701-4710 of 7028 results for "".
- Analysis: GLP-1 Receptor Agonists Linked with Reduced Surgical/Hospitalization Burden in HShttps://practicaldermatology.com/news/analysis-glp-1-receptor-agonists-reduced-surgical-and-hospitalization-burden-in-hs/2483172/New real-world data suggest that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are linked with reduced surgical interventions and hospitalizations in patients with hidradenitis suppurativa (HS). Researchers using real
- New Biomarkers Linked to Atopic Dermatitis Severityhttps://practicaldermatology.com/news/new-biomarkers-linked-to-atopic-dermatitis-severity/2475296/New data published in JID Innovations shows elevated levels of immune cells in patients with atopic dermatitis (AD).
- Blended Wavelength Laser Hair Removal Demonstrates Safety and Efficacy Across Skin Toneshttps://practicaldermatology.com/news/blended-wavelength-laser-hair-removal-demonstrates-safety-and-efficacy-across-skin-tones/2474667/New data demonstrates how dual-wavelength laser devices may offer a safer, more inclusive approach to hair removal for all skin tones. At the recent American Society for Laser Medicine and Surgery (ASLMS) annual meeting, Nkemjika Ugonabo, MD, MPH, FAAD, Assistant Professor at Albert Einste
- Continuous Abrocitinib Use Linked to Better Long-Term AD Outcomes: Studyhttps://practicaldermatology.com/news/continuous-abrocitinib-use-linked-to-better-long-term-ad-outcomes-study/2473925/A new real-world study suggests that sustained abrocitinib treatment and adherence to the full 12-week induction phase improved outcomes and delay relapse in patients with moderate to severe atopic dermatitis (AD). "Although c
- No Link Between PCSK9 Inhibitors and Vitiligo Risk: Studyhttps://practicaldermatology.com/news/analysis-no-link-between-pcsk9-inhibitors-and-vitiligo-risk/2471859/New research published in the Journal of Investigative Dermatology shows no evidence linking PCSK9 inhibitors to an increased risk of vitiligo. Researchers exploring whether inhibiting PCSK9
- Research Letter: Molecule Enhances Skin Barrier, Reduces Retinoid Side Effectshttps://practicaldermatology.com/news/research-letter-molecule-enhances-skin-barrier-reduces-retinoid-side-effects/2471610/A formulation containing Epicutis Skincare’s proprietary TSC molecule significantly reduced erythema and dryness caused by tretinoin, according to a research letter published in the Journal of Cosmetic Dermatology.
- Psoriasis Pipeline: What's Here and What's Coming in Orals, Biologics, and Beyondhttps://practicaldermatology.com/news/psoriasis-pipeline-orals-biologics-and-beyond/2471551/
- Beyond the Surface: Updates in Itch Treatmenthttps://practicaldermatology.com/news/beyond-the-surface-updates-in-itch-treatment/2471285/
- Dr. Lebwohl: Don't Delay GPP Treatment for TB Testing or Skin Biopsyhttps://practicaldermatology.com/news/Dr-Lebwohl-Dont-Delay-GPP-Treatment-TB-Testing-Skin-Biopsy/2471222/Generalized pustular psoriasis (GPP) treatment should not be delayed while waiting for a tuberculosis screening, according to Mark Lebwohl, MD. Speaking at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, Dr. Lebwohl recommended initiating spesolimab therapy immediately
- Literature Review Examines Need for Better Treatment of PsO in Skin of Colorhttps://practicaldermatology.com/news/Literature-Review-Examines-Need-Better-Treatment-PsO-Skin-Color/2471097/A recent literature review on psoriasis in patients with skin of color (SOC) “invokes an important call to action by the [International Psoriasis Council],” its authors wrote I the International Journal of Dermatology. “Education on diagnosing and treating psoriasis in all populations, inc